Home

kana auta kuihtua ac 225 psma rakentaminen serafi Tie talo

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic  Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine

PSMAtreatment - What is actinium PSMA - PSMA Forum
PSMAtreatment - What is actinium PSMA - PSMA Forum

Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with  [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer |  Journal of Nuclear Medicine
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177  and actinium-225 | EJNMMI Research | Full Text
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225 | EJNMMI Research | Full Text

225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate  cancer: a pilot study.
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic  Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine

A) 68 Ga-PSMA-11 PET/CT scan of patient with pretherapeutic tumor... |  Download Scientific Diagram
A) 68 Ga-PSMA-11 PET/CT scan of patient with pretherapeutic tumor... | Download Scientific Diagram

Lu-177 PSMA therapy vs Ac-225 PSMA therapy
Lu-177 PSMA therapy vs Ac-225 PSMA therapy

PSMA Lu-177 x Ac-225 - Oncidium Foundation
PSMA Lu-177 x Ac-225 - Oncidium Foundation

Efficacy and safety of Ac-225-PSMA-617 TAT in Prostate Cancer - Oncidium  Foundation
Efficacy and safety of Ac-225-PSMA-617 TAT in Prostate Cancer - Oncidium Foundation

Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic  castration-resistant Prostate Cancer patients
Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients

Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic  castration-resistant Prostate Cancer patients
Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients

18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle  radiotherapy response | Scientific Reports
18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports

Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in  mCRPC | European Journal of Nuclear Medicine and Molecular Imaging
Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC | European Journal of Nuclear Medicine and Molecular Imaging

⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... |  Download Scientific Diagram
⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram

Frontiers | Current role of prostate-specific membrane antigen-based  imaging and radioligand therapy in castration-resistant prostate cancer
Frontiers | Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer

Ac-225 PSMA therapy
Ac-225 PSMA therapy

225Ac-PSMA-617 for Therapy of Prostate Cancer - ScienceDirect
225Ac-PSMA-617 for Therapy of Prostate Cancer - ScienceDirect

Brazilian Journal Of Oncology - Metastatic castration-resistant prostate  cancer (mCRPC) treated with 225Ac-PSMA-617. Case report
Brazilian Journal Of Oncology - Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report

Cancers | Free Full-Text | [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of  Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA -617
Cancers | Free Full-Text | [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA -617

First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC  patients - Oncidium Foundation
First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients - Oncidium Foundation

Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for  Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC

Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... |  Download Scientific Diagram
Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram

Synthesis of 225Ac-PSMA-617 for Preclinical Use | Bentham Science
Synthesis of 225Ac-PSMA-617 for Preclinical Use | Bentham Science